Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension

Phase 2TerminatedNCT05135000

Novartis Pharmaceuticals47 enrolled

Overview

The purpose of this study was to explore the efficacy and safety of LTP001 in participants with pulmonary arterial hypertension (PAH) to determine if LTP001 had an adequate clinical profile to warrant further clinical development in this indication.

This study was a non-confirmatory, randomized, participant- and investigator-blinded, placebo controlled trial evaluating the efficacy and safety of LTP001 on top of standard of care in participants with PAH. The study included a screening period of up to 8 weeks, followed by a 24-week treatment phase with daily dosing and visits scheduled approximately every 4 weeks. One follow-up visit, which also served as the end-of-study visit, was conducted approximately 30 days after the conclusion of the treatment phase. The total duration of the study, from the beginning of the screening period to the end-of-study visit, was approximately 37 weeks. A total of 44 participants were planned to be randomized in a 3:1 ratio to receive either LTP001 6 mg or placebo.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Pulmonary Arterial Hypertension

Interventions

LTP001DRUG

LTP001, 6 mg, was administered orally once daily in the morning

PlaceboDRUG

Placebo to LTP001 was administered once daily in the morning

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * History of PAH belonging to one of the following subgroups of the Clinical Classification Group 1 (WHO): * participants with idiopathic pulmonary arterial hypertension (IPAH) * Hereditary pulmonary arterial hypertension * Congenital heart disease (surgically repaired at least 12 months prior to screening) * drug or toxin induced (for example, anorexigen, or methamphetamine use). * Resting mean pulmonary arterial pressure (mPAP) \> 25 mmHg; pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic pressure \< 15 mmHg, as determined by right heart catheterization within 20 days of randomization. * Pulmonary Vascular Resistance \> 6 Wood units (480 dynes s/cm-5), as determined by right heart catheterization within 20 days of randomization. * WHO Functional Class II-III * 6MWD must be between 150 and 550 m (inclusive). The qualifying test needs to be within 20 days of randomization. To meet the above criterion additional six minute walk test (6MWT) may be performed up to a maximum of 3 tests in total prior to dosing; the minimal time difference between two tests should be at least 4 h. * Standard of care therapy which is stable at least 6 weeks prior to RHC and qualifying 6MWT assessment within 20 days of randomization. Standard of care includes one or more of the following treatments: * prostacyclin analogues and receptor agonists (if I.V., dose adjustments must be within 20% of initial stable dose) * endothelin receptor antagonists (ERAs) * phosphodiesterase type 5 inhibitors (PDE5i) * soluble guanylate cyclase (sGC) stimulators Exclusion Criteria: * Participants with pulmonary hypertension (PH) in the Clinical Classification Groups 2-5 (WHO), and any PAH Group 1 subgroups not covered by Inclusion Criterion #4. * Participants with a history of left sided heart disease, chronic left sided heart failure, congenital or acquired valvular disease compromising left ventricular function and/or pulmonary venous hypertension or symptomatic coronary disease (non-symptomatic, revascularized coronary artery disease would be acceptable). * Participants with obstructive lung disease defined as: FEV1/FVC \< 60% and FEV1 \< 60% of predicted value after bronchodilator administration as well as participants with moderate or severe restrictive lung disease: Total Lung Capacity \< 70% of predicted value. Testing must have occurred within 24months of screening. If historical testing is not available, then lung function testing must be conducted during the screening period. * Acute or chronic impairment (other than dyspnea), which would limit the ability to comply with study requirements, including interference with physical activity and execution of study procedures such as 6MWT (e.g., angina pectoris, claudication, musculoskeletal disorder, multiple sclerosis, need for walking aids).

Locations (15)

Pulmonary Associates PA

Mesa, Arizona, United States

Medical Univ of South Carolina

Charleston, South Carolina, United States

Novartis Investigative Site

Caba, Buenos Aires, Argentina

Outcomes

Primary Outcomes

Change From Baseline in Right Heard Catheterization Pulmonary Vascular Resistance (PVR) at Week 25

PVR was defined as the resistance against blood flow from the pulmonary artery to the left atrium measured in dyn.s.cm-5

Time frame: Baseline, Week 25

Secondary Outcomes

Change From Baseline in Six Minute Walk Distance (6MWD)

6MWD test measures the distance that a patient can walk on a flat, hard surface in a period of 6 minutes

Time frame: Baseline, Weeks 13 and 25

Change From Baseline in Right Atrium (RA) Pressures at Week 25

The Right Heart Catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including RA pressures.

Time frame: Baseline, Week 25

Change From Baseline in Pulmonary Capillary Wedge Pressure at Week 25

Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including pulmonary capillary wedge pressure (PCWP).

Time frame: Baseline, Week 25

Change From Baseline in Mean Pulmonary Artery Pressure at Week 25

Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including pulmonary artery pressure.

Time frame: Baseline, Week 25

Change From Baseline in Average Cardiac Output (CO) at Week 25

Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including cardiac output (CO).

Time frame: Baseline, Week 25

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.